Some members of a series of novel pyrrolo-1,sbenzoxazepines (PBOXs) potently induce apoptosis in a number of human cancerous cell lines including HL-60 cells and the drug-resistant chronic myelogenous leukaemia cell line, KS62.
Introduction
A novel series of pyrrolo-1,s-benzoxazepines (PBOXs), which are high affinity ligands of the peripheral-type benzodiazepine receptor (PBR) were synthesized recently [l] . We have observed Key words: apoptosis, caspases, c-Jun N-terminal kinase. pyrrolo-I S-benzoxazepines. Abbeviations used: ATF2. activating transcription factor 2; JNK. c-Jun N-terminal kinase: MAPK. mitogen-activated protein kinase: PBOX, pymlo-1.5-benzoxazepine: PBR. peripheral-type benzodiazepine receptor. 'To whom correspondence should be addressed (e-mail dzistrerctr tcd.ie).
that some of these compounds induce apoptosis in a number of cancerous cells including HL-60 cells [2] and the drug-resistant chronic myelogenous leukaemia cell line, K562 [3], which suggests their potential as novel chemotherapeutic agents. In this study we examined further the mechanism by which these novel PBOX compounds induce apoptosis. Because all these compounds reportedly bind to PBR we determined whether this receptor was involved in the mechanism. Caspases, a family of cysteine proteases, play a critical role in the execution phase of apoptosis and are responsible for the cleavage and degradation of cellular proteins [4]. T h e involvement of caspases in PBOX-6-induced apoptosis was also determined. In addition, activation of mitogen-activated protein kinase (MAPK) cascades, such as p38 MAPK and c-Jun N-terminal kinase (JNK), have been shown to play an integral part in the mechanism underlying many apoptotic pathways [S] . We assessed the role of J N K in PBOX-6-induced apoptotic cell death signalling.
Experimental
HL-60 and K562 cells were grown in suspension culture as described previously [2, 3] . Cells were treated with a representative apoptotic PBOX compound, PBOX-6 (10 pM), cytocentrifuged onto glass slides and stained with eosin/methylene blue. T h e degree of apoptosis was determined by counting the cells as previously described [2] . Fluorogenic assays of caspase-3-like protease activity and radioligand binding assays of HL-60 cell homogenates were determined as described in [2] . For measurement of active (phosphorylated) J N K , 5 x lo6 cells were harvested by centrifugation at SOOg for 10 min at 4 "C. After being washed once with ice-cold PBS, the cell pellet was suspended in loop1 of ice-cold lysis buffer [SO mM Tris/HCl (pH 8.0), 150 m M NaCI, 0.1 ()(, (w/v) SDS, l o o (w/v) Triton X-100, 1 m M sodium orthovanadate, 1 m M phenylmethylsulfonyl fluoride, 1 pg/ml leupeptin and 10 pg/ml aprotinin]. Samples were incubated on ice for 15 min and then centrifuged at 20000 g for 20 min.
T h e resulting supernatants were stored at -70 "C until measurement of J N K activity.
T o measure the activity of the J N K substrate activating transcription factor 2 (ATF2), K562 cells were transiently transfected with a pFA-ATF2 trans reporting system, using FuGene6 transfection reagent. T h e pFA-ATF2 plasmid consists of the activation domain of ATF2 fused to the DNA-binding domain (DBD) of yeast GAL4, which is inserted into the pFAcytomegalovirus (CkIV) mammalian expression vector. Cells were co-transfected with pFA-ATF2, a luciferase reporter plasmid, pFR-luc and Jip-1 (inhibitor of J N K signalling pathway) and treated with vehicle (1 "(, ethanol) or 10 p M PBOX-6. Phosphorylation of the activation domain of ATF2 will activate transcription of the luciferase gene from the reporter plasmid. Expression levels of luciferase reflect the activation status of signalling events. After treatment, cells were collected by centrifugation at 500 g for 5 min and washed once in PBS. T h e cell pellets were Iysed using passive Iysis buffer (Promega) and luminescence was measured as described by the manufacturer's instructions. Luminescence readings were corrected for /I-galactosidase activity and expressed as a fold increase over the control values.
Results and discussion
We have recently shown how some members of a new class of compounds, PBOXs, induce apoptosis in a number of human cancerous cell lines such as HL-60 cells and the drug resistant chronic myelogenous leukaemia cell line, K562 [2, 3] . This may suggest their potential as novel chemotherapeutic agents in the treatment of drug-resistant cancers. We thus further examined the mechanism by which these compounds induce apoptosis.
Because all of these compounds bind with high affinity to PBR, we examined whether this receptor was involved in the mechanism by which these compounds cause apoptosis. HL-60 cell homogenates displayed saturable high affinity binding of ['HIPK 11 195, a selective ligand for the PBR, yielding K,, and B,,, values of 17.7 f 5.0 nM and 9.5 f 1.5 pmol/mg of protein respectively. All PBOX compounds screened were shown to inhibit [SH]PK 11 195 binding to HL-60 homogenates with Ki values between 1 and 7 nM, yet micromolar concentrations were required to induce apoptosis [2] . In addition, PBOX compounds induced apoptosis in PBR-deficient Jurkat Tcells, with a similar potency to that observed in HL-60 cells. These results suggest that the rnechanism by which these PBOX compounds induce apoptosis does not involve their interaction with PBR.
A unique family of cysteine proteases, the caspases, appear to play a critical role in initiating and sustaining the biochemical events that occur during apoptotic cell death. PBOX-6, a representative apoptotic PBOX compound, caused a doseand time-dependent activation of caspase-3-like proteases in HL-60 and K562 cells that correlated with the observed morphological effects of apoptosis. Pretreatment of cells for 1 h with the caspase-3-like protease inhibitor, z-DEVD-fmk, reduced the activity of caspase-3-like proteases in both cell types but inhibited PBOX-6-induced apoptosis in HL-60 cells only [2, 3] . This suggests that the activity of caspase-3-like proteases is an essential part of the mechanism by which PBOX-6 induces apoptosis in HL-60 cells, but lip-I blocks PBOX-6-induced phosphorylation of ATFZ and reduces the extent of apoptosis induced K562 cells were co-transfected with the ATFZ trans reporting system and with or without lip-I, followed by treatment wlth either vehicle ( I % ethanol) or PBOX-6 ( I0 pM). Cell lysates were prepared and luciferase activity was measured using a luminometer. The extent of apoptosis was determined by staining and counting slides.
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that the activity of these caspases plays a less important role in K562 cells. J N K , a member of the MAPK family is activated in response to many stressful situations, including heat shock, UV irradiation, protein synthesis inhibitors, inflammatory cytokines and chemotherapeutic drugs [5] . In the present study we determined whether J N K plays a role in the cellular response to PBOX compounds. PBOX-6 treatment of K562 cells resulted in a transient activation of J N K as determined by immunoblotting cell lysates with an antibody that was directed against the phosphorylated form of J N K (Figure 1) . Activation of J N K first became ap-0 2001 Biochemical Society parent at 15 min, peaked between 30 and 45 min and slowly returned to basal levels thereafter. Measurement of ATF2 phosphorylation, a J N K substrate, was also performed by co-transfecting K562 cells with the pFA-ATF2 plasmid and a luciferase reporter plasmid, as described in the Experimental section. PBOX-6 induced a 5-fold stimulation of ATF2 activation over untreated K562 cells whereas vehicle treatment had no effect (Figure 2) . Inhibition of J N K signalling events by co-transfection of cells with the Jip-1 scaffold protein prevented PBOX-6-induced phosphorylation of ATF2 and also reduced the extent of apoptosis induced by the compound, as determined by cell staining (Figure 2) . These results outline the importance of J N K in the signalling pathway in which this compound induces apoptosis.
In conclusion, we have described a series of novel apoptotic agents and indicated the potential of these compounds for use as anticancer drugs. Although we have elucidated some of the signalling pathway by which these compounds induce apoptosis, more work is required to piece together the events occurring upstream of J N K activation.
